IGC PHARMA, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.3M | $911.0K | $397.0K | $898.0K | $4.1M | $5.1M | $2.2M |
| Cost of Revenue | $652.0K | $612.0K | $469.0K | $203.0K | $785.0K | $4.0M | $5.0M | $2.1M |
| Gross Profit | $619.0K | $733.0K | $442.0K | $194.0K | $113.0K | $115.0K | $132.0K | $82.0K |
| Gross Margin | 48.7% | 54.5% | 48.5% | 48.9% | 12.6% | 2.8% | 2.6% | 3.7% |
| Operating Expenses | ||||||||
| Research & Development | $3.7M | $3.8M | $3.5M | $2.3M | $929.0K | $1.0M | $1.3M | $137.0K |
| SG&A Expense | $4.4M | $6.8M | $8.6M | $13.3M | $7.9M | $6.0M | $3.5M | $1.7M |
| Operating Income | $-7.4M | $-9.8M | $-11.6M | $-15.4M | $-8.7M | $-6.9M | $-4.6M | $-1.8M |
| Operating Margin | -585.8% | -728.5% | -1,270.1% | -3,886.1% | -971.5% | -168.6% | -90.8% | -81.6% |
| Interest Expense | $5.0K | $5.0K | $5.0K | $5.0K | $3.0K | — | — | $30.7K |
| Pretax Income | $-7.1M | $-13.0M | $-11.5M | $-15.0M | $-8.8M | $-7.3M | $-4.1M | $-1.8M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $2.0K | $0 |
| Net Income | $-7.1M | $-13.0M | $-11.5M | $-15.0M | $-8.8M | $-7.3M | $-4.1M | $-1.8M |
| Net Margin | -560.3% | -966.5% | -1,263.0% | -3,782.4% | -981.2% | -179.6% | -80.1% | -81.4% |
| EPS (Basic) | $-0.09 | $-0.22 | — | — | $-0.21 | $-0.19 | $-0.13 | $-0.06 |
| EPS (Diluted) | $-0.09 | $-0.22 | — | — | $-0.21 | $-0.19 | $-0.13 | $-0.06 |
| Shares Outstanding (Basic) | 76.5M | 58.8M | 52.6M | 50.0M | 42.0M | 39.5M | 35.4M | 27.9M |
| Shares Outstanding (Diluted) | 76.5M | 58.8M | 52.6M | 50.0M | 42.0M | 39.5M | 35.4M | 27.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |